Fresenius has published its updated Human Rights Statement and reaffirms its commitment to respecting human rights across its operations, value chains and business relationships. The statement explains how human rights are addressed throughout the company, including clear responsibilities, risk-based due diligence processes, preventive and remedial measures, and reporting channels for potential misconduct.
As a global healthcare company, Fresenius has a responsibility toward patients, employees, business partners and the communities in which it operates. Respect for human rights is therefore an important principle that guides responsible business conduct across the Group.
The updated statement gives an overview of Fresenius’ approach to human rights and introduces five human rights priority areas. These highlight the topics that are most closely connected to the company's business activities and where impact on people may be most relevant.
The Human Rights Statement is available here: Human Rights Statement | FSE
- Marc-Alexander Mahl appointed to the Fresenius Management Board; Mahl succeeds Pierluigi Antonelli and will be responsible for the Fresenius Kabi businesses
- Fresenius CFO Sara Hennicken’s contract extended for another five years
- Sébastien Guery assumes overall responsibility for the Nutrition business at Fresenius Kabi
- Leadership team set for the next phase of #FutureFresenius
The Supervisory Board of Fresenius has unanimously appointed Dr. Marc-Alexander Mahl (58) to the Fresenius Management Board, effective November 1, 2026. He will be responsible for the Fresenius Kabi businesses. Mahl succeeds Pierluigi Antonelli, who is leaving the company for personal reasons. At the same time, the Supervisory Board has extended the contract of Chief Financial Officer (CFO) Sara Hennicken (46) for another five years. Her contract will therefore run until 2032.
“On behalf of the Supervisory Board, I would like to thank Pierluigi Antonelli for our successful collaboration built on mutual trust. Thanks to the consistent implementation of #FutureFresenius at Fresenius Kabi, all businesses are now excellently positioned in their respective growth markets and make a significant contribution to the company’s success. We wish Mr. Antonelli all the very best in his future endeavors,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. He added: “At the same time, I am delighted that in Marc-Alexander Mahl we have been able to bring an accomplished physician and experienced executive with more than 20 years of leadership experience at Fresenius to the Group Management Board. He is already responsible for two strategically important businesses, Pharma and Nutrition, and has played a key role in shaping their strategic direction as part of #FutureFresenius. The focus now is on consistently expanding the Biopharma, MedTech and Nutrition growth vectors. We very much look forward to working with him in his expanded role and are confident that he will continue the growth trajectory of all Fresenius Kabi businesses.”
Marc-Alexander Mahl will continue to lead the Pharma Business Unit. Given its growing strategic importance, the Nutrition business will in future be managed as a standalone Business Unit under the leadership of Sébastien Guery. Guery has been responsible for the Nutrition business since April 2024 and previously held several management positions at other international companies, including Sandoz, DuPont Nutrition & Biosciences and McKinsey. In his expanded role, Guery will report directly to Marc-Alexander Mahl, who is responsible for the Fresenius Kabi businesses on the Fresenius Management Board.
At the same time, the Supervisory Board has extended the contract of CFO Sara Hennicken for another five years. Her contract will now run until 2032. "Sara Hennicken has played a pivotal role in shaping the successful execution of #FutureFresenius from the very beginning. Thus, we very much look forward to continuing our successful collaboration with her," said Kirsch.
“I would like to congratulate Sara Hennicken and Marc-Alexander Mahl and very much look forward to continuing our work together on the Management Board. On behalf of the Management Board, I would also like to thank Pierluigi Antonelli for the excellent collaboration over the past years and wish him all the very best for the future. Looking ahead, the medical nutrition business will play an even more important role for the company as a whole. I am therefore very pleased that Sébastien Guery will now assume overall responsibility for the Nutrition business,” added Michael Sen, Chief Executive Officer of Fresenius.
Leadership team set for the next phase of #FutureFresenius
With these decisions and the further strengthening of its operating businesses, Fresenius is putting its leadership team in place for the next phase of #FutureFresenius and underscoring its ambition to create sustainable value through profitable, innovation-driven growth.
Dr. Marc-Alexander Mahl has headed Fresenius’ Pharma and Nutrition businesses since May 2023. In addition, he oversees sustainability activities in these businesses. Mahl has been with Fresenius since July 2001, with a brief interruption, and has since held various management positions with regional and global responsibilities. Since 2011, he has been responsible for the global Pharma business. In parallel, Mahl served as President of Medicines for Europe and as a member of the Executive Committee of the German industry association for specialized nutrition. Mahl studied medicine, is a specialist in transfusion medicine and holds an MBA from INSEAD.
Sara Hennicken has been Chief Financial Officer of Fresenius since September 2022. In this role, she is responsible for Finance, IT and Cybersecurity. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to that, she spent 14 years in investment banking, most recently serving as Managing Director at Deutsche Bank. From 2005 to 2010, Hennicken worked at Citigroup in Frankfurt and London. She studied economics in Germany and the United States.
About Fresenius
Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany. In the full-year 2025, Fresenius generated €22.6 billion (excluding special items) in annual revenue. Fresenius employs more than 178,000 people. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in the separately listed Fresenius Medical Care AG. With around 140 hospitals, 330 outpatient facilities and 300 occupational risk prevention centres, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 27 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.
For more information, visit fresenius.com and follow Fresenius Investor Relations on LinkedIn.
About Fresenius Medical Care
Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25%; Fresenius Medical Care's results are not consolidated in the Fresenius Group's revenue and earnings.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Correspondence Address
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu
Chairman of the Supervisory Board: Wolfgang Kirsch
Securities Information
Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.
ISIN: DE000FRE5EN2 ● German Securities Code: FRE5EN
American Depository Receipts
Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.
ISIN: US35804M1053 ● CUSIP: 35804M105
Contacts
For Media contacts, click here, and to contact Investor Relations, click here.
- Marc-Alexander Mahl appointed to the Fresenius Management Board; Mahl succeeds Pierluigi Antonelli and will be responsible for the Fresenius Kabi businesses
- Fresenius CFO Sara Hennicken’s contract extended for another five years
- Sébastien Guery assumes overall responsibility for the Nutrition business at Fresenius Kabi
- Leadership team set for the next phase of #FutureFresenius
The Supervisory Board of Fresenius has unanimously appointed Dr. Marc-Alexander Mahl (58) to the Fresenius Management Board, effective November 1, 2026. He will be responsible for the Fresenius Kabi businesses. Mahl succeeds Pierluigi Antonelli, who is leaving the company for personal reasons. At the same time, the Supervisory Board has extended the contract of Chief Financial Officer (CFO) Sara Hennicken (46) for another five years. Her contract will therefore run until 2032.
“On behalf of the Supervisory Board, I would like to thank Pierluigi Antonelli for our successful collaboration built on mutual trust. Thanks to the consistent implementation of #FutureFresenius at Fresenius Kabi, all businesses are now excellently positioned in their respective growth markets and make a significant contribution to the company’s success. We wish Mr. Antonelli all the very best in his future endeavors,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. He added: “At the same time, I am delighted that in Marc-Alexander Mahl we have been able to bring an accomplished physician and experienced executive with more than 20 years of leadership experience at Fresenius to the Group Management Board. He is already responsible for two strategically important businesses, Pharma and Nutrition, and has played a key role in shaping their strategic direction as part of #FutureFresenius. The focus now is on consistently expanding the Biopharma, MedTech and Nutrition growth vectors. We very much look forward to working with him in his expanded role and are confident that he will continue the growth trajectory of all Fresenius Kabi businesses.”
Marc-Alexander Mahl will continue to lead the Pharma Business Unit. Given its growing strategic importance, the Nutrition business will in future be managed as a standalone Business Unit under the leadership of Sébastien Guery. Guery has been responsible for the Nutrition business since April 2024 and previously held several management positions at other international companies, including Sandoz, DuPont Nutrition & Biosciences and McKinsey. In his expanded role, Guery will report directly to Marc-Alexander Mahl, who is responsible for the Fresenius Kabi businesses on the Fresenius Management Board.
At the same time, the Supervisory Board has extended the contract of CFO Sara Hennicken for another five years. Her contract will now run until 2032. "Sara Hennicken has played a pivotal role in shaping the successful execution of #FutureFresenius from the very beginning. Thus, we very much look forward to continuing our successful collaboration with her," said Kirsch.
“I would like to congratulate Sara Hennicken and Marc-Alexander Mahl and very much look forward to continuing our work together on the Management Board. On behalf of the Management Board, I would also like to thank Pierluigi Antonelli for the excellent collaboration over the past years and wish him all the very best for the future. Looking ahead, the medical nutrition business will play an even more important role for the company as a whole. I am therefore very pleased that Sébastien Guery will now assume overall responsibility for the Nutrition business,” added Michael Sen, Chief Executive Officer of Fresenius.
Leadership team set for the next phase of #FutureFresenius
With these decisions and the further strengthening of its operating businesses, Fresenius is putting its leadership team in place for the next phase of #FutureFresenius and underscoring its ambition to create sustainable value through profitable, innovation-driven growth.
Dr. Marc-Alexander Mahl has headed Fresenius’ Pharma and Nutrition businesses since May 2023. In addition, he oversees sustainability activities in these businesses. Mahl has been with Fresenius since July 2001, with a brief interruption, and has since held various management positions with regional and global responsibilities. Since 2011, he has been responsible for the global Pharma business. In parallel, Mahl served as President of Medicines for Europe and as a member of the Executive Committee of the German industry association for specialized nutrition. Mahl studied medicine, is a specialist in transfusion medicine and holds an MBA from INSEAD.
Sara Hennicken has been Chief Financial Officer of Fresenius since September 2022. In this role, she is responsible for Finance, IT and Cybersecurity. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to that, she spent 14 years in investment banking, most recently serving as Managing Director at Deutsche Bank. From 2005 to 2010, Hennicken worked at Citigroup in Frankfurt and London. She studied economics in Germany and the United States.
Images for Editorial Use:
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu
Chairman of the Supervisory Board: Wolfgang Kirsch
Fresenius announced today that the Company's Q3 2026 Aide Memoire is now available on the Company's Investor Relations overview section.
As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q3 2026 financial results will be published on November 4, 2026.
